|
1
|
Gupta J, Gantyala SP, Kashyap S and Tandon
R: Diagnosis, management, and histopathological characteristics of
corneal keloid: A case series and literature review. Asia Pac J
Ophthalmol (Phila). 5:354–359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jeon YR, Ahn HM, Choi IK, Yun CO, Rah DK,
Lew DH and Lee WJ: Hepatocyte growth factor-expressing adenovirus
upregulates matrix metalloproteinase-1 expression in keloid
fibroblasts. Int J Dermatol. 55:356–361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Syed F, Singh S and Bayat A: Superior
effect of combination vs. single steroid therapy in keloid disease:
A comparative in vitro analysis of glucocorticoids. Wound Repair
Regen. 21:88–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Har-Shai Y and Zouboulis CC: Intralesional
cryotherapy for the treatment of keloid scars: A prospective study.
Plast Reconstr Surg. 136:397e–398e. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee MJ, Kim DH, Ryu JS, Ko AY, Ko JH, Kim
MK, Wee WR, Khwarg SI and Oh JY: Topical TSG-6 administration
protects the ocular surface in two mouse models of
inflammation-related dry eye. Invest Ophthalmol Vis Sci.
56:5175–5181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JA, Ko JH, Ko AY, Lee HJ, Kim MK, Wee
WR, Lee RH, Fulcher SF and Oh JY: TSG-6 protects corneal
endothelium from transcorneal cryoinjury in rabbits. Invest
Ophthalmol Vis Sci. 55:4905–4912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baranova NS, Nilebäck E, Haller FM, Briggs
DC, Svedhem S, Day AJ and Richter RP: The inflammation-associated
protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6
oligomers. J Biol Chem. 286:25675–25686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan KT, McGrouther DA, Day AJ, Milner CM
and Bayat A: Characterization of hyaluronan and TSG-6 in skin
scarring: Differential distribution in keloid scars, normal scars
and unscarred skin. J Eur Acad Dermatol Venereol. 25:317–327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mahoney DJ, Swales C, Athanasou NA,
Bombardieri M, Pitzalis C, Kliskey K, Sharif M, Day AJ, Milner CM
and Sabokbar A: TSG-6 inhibits osteoclast activity via an autocrine
mechanism and is functionally synergistic with osteoprotegerin.
Arthritis Rheum. 63:1034–1043. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kehlen A, Pachnio A, Thiele K and Langner
J: Gene expression induced by interleukin-17 in fibroblast-like
synoviocytes of patients with rheumatoid arthritis: Upregulation of
hyaluronan-binding protein TSG-6. Arthritis Res Ther. 5:R186–R192.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Chen Z, Li XJ, Ma L and Tang YL:
Anti-inflammatory cytokine TSG-6 inhibits hypertrophic scar
formation in a rabbit ear model. Eur J Pharmacol. 751:42–49. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang GY, Yi CG, Li X, Zheng Y, Niu ZG,
Xia W, Meng Z, Meng CY and Guo SZ: Inhibition of vascular
endothelial growth factor expression in keloid fibroblasts by
vector-mediated vascular endothelial growth factor shRNA: A
therapeutic potential strategy for keloid. Arch Dermatol Res.
300:177–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hochman B, Isoldi FC, Furtado F and
Ferreira LM: New approach to the understanding of keloid:
Psychoneuroimmune-endocrine aspects. Clin Cosmet Investig Dermatol.
8:67–73. 2015.PubMed/NCBI
|
|
14
|
Parikh DA, Ridgway JM and Ge NN: Keloid
banding using suture ligature: A novel technique and review of
literature. Laryngoscope. 118:1960–1965. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong X, Li X and Ning J: Expression of
TSG-6 and its significance in pathological scar. Acta Univ Med
Anhui. 48:685–687. 2013.(In Chinese).
|
|
16
|
Milner CM, Higman VA and Day AJ: TSG-6: A
pluripotent inflammatory mediator? Biochem Soc Trans. 34:446–450.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park Y, Jowitt TA, Day AJ and Prestegard
JH: Nuclear magnetic resonance insight into the multiple
glycosaminoglycan binding modes of the link module from human
TSG-6. Biochemistry. 55:262–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagyeri G, Radacs M, Ghassemi-Nejad S,
Tryniszewska B, Olasz K, Hutas G, Gyorfy Z, Hascall VC, Glant TT
and Mikecz K: TSG-6 protein, a negative regulator of inflammatory
arthritis, forms a ternary complex with murine mast cell tryptases
and heparin. J Biol Chem. 286:23559–23569. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baranova NS, Foulcer SJ, Briggs DC,
Tilakaratna V, Enghild JJ, Milner CM, Day AJ and Richter RP:
Inter-a-inhibitor impairs TSG-6-induced hyaluronan cross-linking. J
Biol Chem. 288:29642–29653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang S, He H, Day AJ and Tseng SC:
Constitutive expression of inter-a-inhibitor (IaI) family proteins
and tumor necrosis factor-stimulated gene-6 (TSG-6) by human
amniotic membrane epithelial and stromal cells supporting formation
of the heavy chain-hyaluronan (HC-HA) complex. J Biol Chem.
287:12433–12444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang GY, Wu LC, Liao T, Chen GC, Chen YH,
Zhao YX, Chen SY, Wang AY, Lin K, Lin DM, et al: A novel regulatory
function for miR-29a in keloid fibrogenesis. Clin Exp Dermatol.
41:341–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L, Wang Y, Liu W and Huang Y: BAMBI
inhibits skin fibrosis in keloid through suppressing TGF-b1-induced
hypernomic fibroblast cell proliferation and excessive accumulation
of collagen I. Int J Clin Exp Med. 8:13227–13234. 2015.PubMed/NCBI
|
|
23
|
Shin JU, Lee WJ, Tran TN, Jung I and Lee
JH: Hsp70 knockdown by siRNA decreased collagen production in
keloid fibroblasts. Yonsei Med J. 56:1619–1626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garcia GE, Wisniewski HG, Lucia MS,
Arevalo N, Slaga TJ, Kraft SL, Strange R and Kumar AP:
2-Methoxyestradiol inhibits prostate tumor development in
transgenic adenocarcinoma of mouse prostate: Role of tumor necrosis
factor-alpha-stimulated gene 6. Clin Cancer Res. 12:980–988. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park JI, Cao L, Platt VM, Huang Z, Stull
RA, Dy EE, Sperinde JJ, Yokoyama JS and Szoka FC: Antitumor therapy
mediated by 5-fluorocytosine and a recombinant fusion protein
containing TSG-6 hyaluronan binding domain and yeast cytosine
deaminase. Mol Pharm. 6:801–812. 2009. View Article : Google Scholar : PubMed/NCBI
|
